LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist: A phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Step 1: Online Questionnaire You answer questions about your medical history, current medications, lifestyle and weight loss goals
Since then, GLP-1 RAs have attracted considerable academic interest, leading to the continuous introduction of innovative analogs into the pharmaceutical industry
Never inject the same spot on consecutive weeks
This synthetic version of the natural hormone glucagon-like peptide-1 (GLP-1) has the dual advantage of regulating blood sugar levels and promoting weight loss
(Lausanne) 11 , 597583 (2020)